{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:45:08Z","timestamp":1779216308477,"version":"3.51.4"},"reference-count":38,"publisher":"Wiley","issue":"18","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune\u2010related adverse events (irAEs) have been linked to improved outcomes in patients undergoing treatment with immune checkpoint inhibitors (ICIs) for various cancers. However, the relationship between irAEs and overall survival (OS) in patients with advanced gastric cancer (AGC) receiving chemoimmunotherapy remains unclear. This study aimed to explore the association between irAEs and treatment outcomes in patients with AGC receiving chemotherapy plus nivolumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study analyzed clinical data from patients with HER2\u2010negative AGC who received first\u2010line chemotherapy (SOX, CapeOX, or FOLFOX) plus nivolumab at the National Cancer Center Hospital between November 2021 and February 2023. Patients were stratified into two groups based on the occurrence of irAEs. Outcomes, including OS and progression\u2010free survival (PFS), were compared using Kaplan\u2013Meier analysis, landmark analysis, and Cox proportional hazards regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 60 patients analyzed, 15 (25%) developed irAEs of any grade, with 3 patients (5%) experiencing grade \u2265\u20093 irAEs. Patients with irAEs had significantly longer OS and PFS in comparison to those without irAEs (median OS: not reached vs. 17.1\u2009months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01; median PFS: not reached vs. 6.8\u2009months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Multivariate analysis identified the occurrence of irAEs as a favorable prognostic factor for OS (hazard ratio: 0.13; 95% CI: 0.03\u20130.59;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study suggests that the occurrence of irAEs is associated with improved survival outcomes in patients with AGC receiving chemotherapy plus nivolumab. IrAEs may serve as a predictive marker for treatment response in this setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71252","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T09:19:53Z","timestamp":1758100793000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Association Between Immune\u2010Related Adverse Events and Treatment Outcomes in Advanced Gastric Cancer Patients Receiving Nivolumab Plus Chemotherapy: A Retrospective Study"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4085-0741","authenticated-orcid":false,"given":"Kazumasa","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology National Cancer Center Hospital  Tokyo Japan"},{"name":"Department of Medical Oncology Toranomon Hospital  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiharu","family":"Hirose","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8922-5227","authenticated-orcid":false,"given":"Hirokazu","family":"Shoji","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuko","family":"Okita","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuo","family":"Takashima","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology National Cancer Center Hospital  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(17)31827\u20105"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)00797\u20102"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(23)00515\u20106"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj\u20102023\u2010078876"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053745"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.13520"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017\u20100384"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2925"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1916"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.2707"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1159\/000518619"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad090"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010019\u20106150\u2010y"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00318"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7711"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010022\u201010133\u20101"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2021.1976942"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01654"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018\u2010021\u201000180\u20101"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd8636"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0402"},{"key":"e_1_2_10_26_2","doi-asserted-by":"crossref","unstructured":"[published correction appears in JAMA Oncology 2019 Jul 1;5(7):1070 https:\/\/doi.org\/10.1001\/jamaoncol.2019.2137].","DOI":"10.1001\/jamaoncol.2019.2137"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abn9644"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4650695"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1309540"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3370"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.790"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100603"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095\u20103941.2021.0052"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12957\u2010022\u201002695\u2010y"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5919"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1004663"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v12.i2.103"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010024\u201082105\u20103"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T08:27:50Z","timestamp":1766219270000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":38,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/cam4.71252"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71252","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2025-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71252"}}